Regeneron Pharmaceuticals
(REGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,045,500 | 1,708,500 | 1,467,700 | 1,087,843 | 917,876 |
| Marketable Securities | 1,624,200 | 1,523,900 | 1,342,200 | 1,104,309 | 765,642 |
| Receivables | 2,455,900 | 2,305,200 | 2,243,200 | 2,202,945 | 2,039,247 |
| Inventories | 1,317,200 | 1,208,800 | 1,151,200 | 1,039,679 | 928,553 |
| TOTAL | $6,651,000 | $6,928,600 | $6,447,600 | $5,719,583 | $4,814,917 |
| Non-Current Assets | |||||
| PPE Net | 2,676,600 | 2,612,800 | 2,575,800 | 2,524,446 | 2,461,614 |
| Investments And Advances | 2,884,600 | 2,339,800 | 1,755,000 | 1,873,569 | 2,044,703 |
| Other Non-Current Assets | 961,400 | 973,600 | 956,100 | 688,015 | 630,746 |
| TOTAL | $6,522,600 | $5,926,200 | $5,286,900 | $5,086,030 | $5,137,063 |
| Total Assets | $13,173,600 | $12,854,800 | $11,734,500 | $10,805,610 | $9,951,980 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 244,000 | 239,600 | 218,200 | 172,361 | 171,906 |
| Other current liabilities | 876,700 | 741,100 | 772,100 | 781,924 | 670,709 |
| TOTAL | $1,713,100 | $1,511,400 | $1,442,800 | $1,417,230 | $1,331,190 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 592,400 | 530,700 | 452,500 | 462,945 | 488,575 |
| Other Non-Current Liabilities | 267,900 | 376,300 | 361,700 | 194,033 | 190,020 |
| TOTAL | $1,704,600 | $1,898,700 | $1,534,400 | $1,520,083 | $1,434,364 |
| Total Liabilities | $3,417,700 | $3,410,100 | $2,977,200 | $2,937,313 | $2,765,554 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 109,832 | 109,639 | 109,277 | 108,235 | 108,056 |
| Common Shares | 100 | 100 | 100 | 112 | 112 |
| Retained earnings | 5,918,200 | 5,725,100 | 5,254,300 | 4,433,904 | 3,839,179 |
| Other shareholders' equity | 16,000 | 2,600 | -12,700 | -10,890 | -11,464 |
| TOTAL | $9,755,900 | $9,444,700 | $8,757,300 | $7,868,300 | $7,186,426 |
| Total Liabilities And Equity | $13,173,600 | $12,854,800 | $11,734,500 | $10,805,613 | $9,951,980 |